NovaBay Pharmaceuticals, Inc.
NBY
$0.60
$0.000.00%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -33.72% | -6.77% | -20.01% | -27.75% | -20.03% |
| Total Other Revenue | -- | -- | -77.50% | -95.00% | -100.00% |
| Total Revenue | -33.47% | -6.45% | -20.21% | -27.95% | -20.22% |
| Cost of Revenue | -32.19% | -43.65% | -48.98% | -54.96% | -38.46% |
| Gross Profit | 4.53% | -22.96% | -36.83% | -41.93% | -40.75% |
| SG&A Expenses | 13.25% | 2.03% | -22.25% | -27.16% | -32.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.68% | -11.77% | -30.51% | -36.28% | -34.55% |
| Operating Income | -20.92% | -38.81% | 6.40% | 8.88% | 24.01% |
| Income Before Tax | 3.56% | -14.65% | 41.09% | 33.58% | 34.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.56% | -14.65% | 41.09% | 33.58% | 34.77% |
| Earnings from Discontinued Operations | 427.76% | 94.91% | -142.13% | -339.03% | -760.41% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 132.94% | 25.07% | 26.34% | 11.99% | 9.16% |
| EBIT | -20.92% | -38.81% | 6.40% | 8.88% | 24.01% |
| EBITDA | -21.53% | -39.57% | 4.48% | 5.16% | 20.26% |
| EPS Basic | 99.49% | 76.04% | 67.18% | 74.18% | 62.61% |
| Normalized Basic EPS | 96.35% | 56.49% | 59.06% | 43.00% | 42.38% |
| EPS Diluted | 99.49% | 76.04% | 67.18% | 74.18% | 62.61% |
| Normalized Diluted EPS | 96.37% | 56.49% | 59.06% | 43.00% | 42.38% |
| Average Basic Shares Outstanding | 3,251.41% | 2,603.04% | 1,436.80% | 545.02% | 169.57% |
| Average Diluted Shares Outstanding | 3,271.15% | 2,603.04% | 1,436.80% | 545.02% | 169.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |